Department of Medicine, Division of Hematology & Oncology, Mayo Clinic, Scottsdale, AZ 85259, USA.
Department of Pathology, Division of Anatomic Pathology & Laboratory Medicine, Mayo Clinic, Scottsdale, AZ 85259, USA.
Immunotherapy. 2018 Sep;10(12):1077-1091. doi: 10.2217/imt-2018-0024.
Despite recent advancements in therapeutic options for advanced hepatobiliary cancers, there remains an unmet need for innovative systemic treatments. Immunotherapy has shown an ability to provide prolonged clinical benefit, but this benefit remains limited to a small subset of patients. Numerous ongoing endeavors are investigating novel immunotherapy concepts. Immunotherapies that have demonstrated clinical efficacy in hepatobiliary cancers include PD-1 inhibitor therapy and CTLA-4 inhibitor therapy. Novel immunotherapy concepts include targeting emerging checkpoint proteins, bispecific T-cell engagers, combinatorial trials with checkpoint inhibitors, oncolytic virotherapy and chimeric antigen receptor T cells. The goal for these new treatment strategies is to achieve a meaningful expansion of patients deriving prolonged clinical benefit from immunotherapy.
尽管在治疗晚期肝胆癌的治疗方法方面取得了一些进展，但仍然需要创新的系统治疗方法。免疫疗法已经显示出提供长期临床获益的能力，但这种获益仍然仅限于一小部分患者。目前正在进行许多研究来探索新的免疫治疗概念。在肝胆癌中已经证明具有临床疗效的免疫疗法包括 PD-1 抑制剂治疗和 CTLA-4 抑制剂治疗。新的免疫治疗概念包括针对新兴检查点蛋白、双特异性 T 细胞衔接器、与检查点抑制剂的联合试验、溶瘤病毒治疗和嵌合抗原受体 T 细胞。这些新的治疗策略的目标是使更多的患者从免疫治疗中获得显著的临床获益。
